A selected and quality assured stem cell product, using a unique marker technology
MSC preparations are usually a heterogenous preparation with various numbers of contaminating cells (such as fibroblasts)
Integrin α10β1-selected MSCs represent homogeneous and consistent preparations of MSCs
Our selected MSCs show a superior ability to adhere to damaged cartilage and exposed subchondral bone in explants
Has shown to reduce lameness and joint pathology
This is likely an effect of the inherent affinity of integrin α10β1 to the exposed collagen
Our research
EQGen’s™ strategic partner (Xintela AB, Sweden) developed the technology and has conducted multiple studies in equines, showing very promising results.
Watch this interview with Dr. Lisa Fortier who was involved in one of our clinical trials to learn more about our the results of our study.
What’s next?
The EQGen™ Team is advancing this next-generation regenerative product by conducting further studies to explore appropriate dose, safety and effectiveness in a larger group of subjects for the global equine market.
We are also developing the product in a different dose for dogs.
